Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.74+0.01 (+0.07%)
Close on Nov 13, 2026Market cap $12.30BP/E 26.9Yield 0.58%
Dr Reddys Laboratories ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2026 it was ₹71.16B, down 20.0% from the year before. Over ten years it grew 6.0% a year on average. The highest annual figure on record is ₹88.90B in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | ₹71.16B | -20.0% |
| FY2025 | Mar 31, 2025 | ₹88.90B | +7.7% |
| FY2024 | Mar 31, 2024 | ₹82.57B | +18.3% |
| FY2023 | Mar 31, 2023 | ₹69.78B | +69.0% |
| FY2022 | Mar 31, 2022 | ₹41.30B | +11.4% |
| FY2021 | Mar 31, 2021 | ₹37.08B | +30.3% |
| FY2020 | Mar 31, 2020 | ₹28.47B | -13.9% |
| FY2019 | Mar 31, 2019 | ₹33.08B | +40.0% |
| FY2018 | Mar 31, 2018 | ₹23.63B | -4.6% |
| FY2017 | Mar 31, 2017 | ₹24.78B | -37.9% |
| FY2016 | Mar 31, 2016 | ₹39.87B | – |
See a number that looks wrong?